Niittykoski M, Hakkarainen V, Puumala T, Lappalainen R, Ruotsalainen S, Haapalinna A, Sirviö J
A.I. Virtanen Institute, University of Kuopio, Finland.
Behav Pharmacol. 1997 Oct;8(5):465-70.
The present study investigated whether an alpha 2-adrenoceptor antagonist (atipamezole) can influence hyperactivity induced by the systemic administration of scopolamine. In the water maze (WM) task, scopolamine (scop) 0.25 mg/kg treatment significantly increased swimming speed during the acquisition phase of this task. Atipamezole (ati) 30 micrograms/kg slightly reduced swimming speed both in saline- and in scop-treated rats. Ati 300 micrograms/kg slightly reduced swimming speed in saline-treated rats, and it prevented the scop-induced increase in swimming speed, because ati300-scop treated rats swam more slowly than the saline-saline group. In addition, ati 300 micrograms/kg reduced the total distance swum in scop-treated rats during a free swim trial (the platform was removed from the pool) performed 1 day after the acquisition phase of the WM test, even though it did not affect this parameter when administered alone. In the open arena task, which assessed the ambulation of rats when the pool was covered with a solid floor, scopolamine dose-dependently increased locomotor activity. The rats ambulated more when treated with scop 0.50 mg/kg compared to vehicle treatment, whereas the effect of scop 0.25 mg/kg treatment did not reach significance. In a test investigating the effects of ati 300 micrograms/kg and scop 0.50 mg/kg given singly or combined, the rats ambulated more during both ati 300 micrograms/kg and scop 0.50 mg/kg treatments given alone, but when combined, the rats ambulated less than during scop-saline treatment even though this was more than during control (saline-saline) treatment. These results indicate that the systemic administration of an alpha 2-antagonist can reduce hyperactivity induced by scopolamine.
本研究调查了一种α2 -肾上腺素能受体拮抗剂（阿替美唑）是否能影响东莨菪碱全身给药所诱发的多动。在水迷宫（WM）任务中，0.25mg/kg的东莨菪碱（scop）处理在该任务的习得阶段显著提高了游泳速度。30微克/千克的阿替美唑（ati）在生理盐水处理组和scop处理组大鼠中均略微降低了游泳速度。300微克/千克的ati在生理盐水处理组大鼠中略微降低了游泳速度，并且它阻止了scop诱导的游泳速度增加，因为ati300 - scop处理组大鼠比生理盐水 - 生理盐水组游得更慢。此外，在WM测试习得阶段后1天进行的自由游泳试验（平台从池中移除）中，300微克/千克的ati降低了scop处理组大鼠的总游泳距离，尽管单独给药时它不影响该参数。在开放场地任务中，该任务评估当池子覆盖有坚实地面时大鼠的移动情况，东莨菪碱剂量依赖性地增加了运动活性。与赋形剂处理相比，0.50mg/kg的scop处理时大鼠移动更多，而0.25mg/kg的scop处理效果未达到显著水平。在一项研究单独或联合给予300微克/千克的ati和0.50mg/kg的scop效果的试验中，单独给予300微克/千克的ati和0.50mg/kg的scop时大鼠移动都更多，但联合给药时，大鼠移动比scop - 生理盐水处理组少，尽管仍比对照（生理盐水 - 生理盐水）处理组多。这些结果表明，α2拮抗剂全身给药可减少东莨菪碱诱导的多动。
